New Moderna jab findings and further evidence for booster

16 September 2021

US biotech Moderna (Nasdaq: MRNA) has highlighted new findings suggesting that the company’s Spikevax COVID-19 vaccine is highly effective against circulating ‘variants of concern’.

They include a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and a separate recent publication by the US Centers for Disease Control and Prevention (CDC).

In a prospective cohort study at KPSC, an analysis of 352,878 recipients of two doses of mRNA-1273 matched to 352,878 unvaccinated individuals found a vaccine effectiveness of 87% against COVID-19 diagnosis and 96% against hospitalization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK